Filter Results:
(926)
Show Results For
- All HBS Web
(926)
- People (2)
- News (70)
- Research (778)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
Show Results For
- All HBS Web
(926)
- People (2)
- News (70)
- Research (778)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
- April 2002
- Supplement
Grey Warner, Merck Latin America
By: Michael Beer
Grey Warner, the vice president of Merck's Latin America region, discusses the challenges raised in the case and the lessons learned. View Details
Keywords: Strategic Planning; Values and Beliefs; Change Management; Problems and Challenges; Management Teams; Pharmaceutical Industry; Latin America
Beer, Michael. "Grey Warner, Merck Latin America." Harvard Business School Video Supplement 402-801, April 2002.
- May 1987
- Teaching Note
Eli Lilly and Co. (A) and (B), Teaching Note
By: William J. Bruns Jr.
Keywords: Pharmaceutical Industry
- June 1999 (Revised October 1999)
- Case
Eli Lilly, 1998 (A): Strategic Challenges
By: Michael Y. Yoshino and Thomas W. Malnight
Deals with key strategic challenges facing Eli Lilly, a highly successful U.S.-based drug company. View Details
Yoshino, Michael Y., and Thomas W. Malnight. "Eli Lilly, 1998 (A): Strategic Challenges." Harvard Business School Case 399-173, June 1999. (Revised October 1999.)
- June 1998
- Supplement
MBA Integrative Exercise: Competition & Strategy, April 1998 , Video
By: Carin-Isabel Knoop
Daniel Vasella, President of Novartis AG, discusses the situation in Indonesia and his ideas of what Suharto should do in the spring of 1998. Drummond Paris, Regional Pharma Head Asia/Pacific, Novartis AG, discusses the opportunities for Novartis in Indonesia and also... View Details
Knoop, Carin-Isabel. "MBA Integrative Exercise: Competition & Strategy, April 1998 , Video." Harvard Business School Video Supplement 898-504, June 1998.
- March 1993
- Supplement
Burroughs Wellcome and AZT (C)
Describes key developments relating to Burroughs Wellcome, AZT and other AIDS drugs, and the AIDS issue in general from late 1989 through 1992. Includes excerpts from Wellcome PLC's financial statements and updated statistics on AIDS in the United States. View Details
Keywords: Health Pandemics; Multinational Firms and Management; Financial Statements; Pharmaceutical Industry; United States
Emmons, Willis M., III. "Burroughs Wellcome and AZT (C)." Harvard Business School Supplement 793-115, March 1993.
- March 1993
- Supplement
Burroughs Wellcome and AZT (B)
Describes Burroughs Wellcome's response to protests over the pricing of its AIDS drug AZT in September 1989. Also presents short-term reactions by government officials, AIDS activists, and investors to Burroughs Wellcome's strategy. View Details
Keywords: Ethics; Health Pandemics; Multinational Firms and Management; Price; Crime and Corruption; Risk and Uncertainty; Business Strategy; Business and Community Relations; Business and Government Relations; Business and Shareholder Relations; Pharmaceutical Industry
Emmons, Willis M., III. "Burroughs Wellcome and AZT (B)." Harvard Business School Supplement 793-114, March 1993.
- March 1997
- Teaching Note
Eli Lilly and Company: Innovation in Diabetes Care TN
By: Clayton M. Christensen and Bret J. Baird
Teaching Note for (9-696-077). View Details
Keywords: Pharmaceutical Industry
- December 1998 (Revised September 1999)
- Case
Novartis: Betting on Life Sciences
By: Ray A. Goldberg, Carin-Isabel Knoop and Srinivas Sunder
The merger of Ciba-Geigy and Sandoz produced genomic-based synergies for health care, agribusiness, and nutritional supplements. How to build on the strength of the individual divisions and provide synergies that would continue Novartis' leadership role is the question... View Details
Keywords: Mergers and Acquisitions; Business Divisions; Health Care and Treatment; Leadership; Product Positioning; Science-Based Business; Corporate Strategy; Pharmaceutical Industry
Goldberg, Ray A., Carin-Isabel Knoop, and Srinivas Sunder. "Novartis: Betting on Life Sciences." Harvard Business School Case 599-076, December 1998. (Revised September 1999.)
- January–February 1994
- Article
Financial Engineering at Merck
By: Timothy A. Luehrman
Luehrman, Timothy A. "Financial Engineering at Merck." Harvard Business Review 72, no. 1 (January–February 1994): 89–99.
- November 18 2004
- Article
Merck's Recall of Rofecoxib: A Strategic Perspective
By: Felix Oberholzer-Gee and Noorein Inamdar
Oberholzer-Gee, Felix, and Noorein Inamdar. "Merck's Recall of Rofecoxib: A Strategic Perspective." New England Journal of Medicine 351, no. 21 (November 18 2004): 2147–2149.
- April 1999 (Revised May 2000)
- Case
Pilgrim Drug Company
David Thomas takes his first sales management assignment and is faced with a sales rep revolt because of a possible territory reorganization. In addition, his sales division is performing well below the national average. Rewritten version of an earlier case. View Details
Burton, M. Diane, and Jeffrey L. Bradach. "Pilgrim Drug Company." Harvard Business School Case 499-062, April 1999. (Revised May 2000.)
- February 26, 2003
- Article
Consumers' Reports on the Health Effects of Direct-To-Consumer Drug Advertising
By: Joel S. Weissman, David Blumenthal, Alvin J. Silk, Kinga Zapert, Michael Newman and Robert Leitman
Weissman, Joel S., David Blumenthal, Alvin J. Silk, Kinga Zapert, Michael Newman, and Robert Leitman. "Consumers' Reports on the Health Effects of Direct-To-Consumer Drug Advertising." Health Affairs (February 26, 2003).
- 12 May 2009
- First Look
First Look: May 12, 2009
illustrates how deep dives guide the formation of a set of new core activities in the variation-selection-retention process. No PDF is available at this time. PublicationsWhat Causes Industry Agglomeration? Evidence from Coagglomeration... View Details
Keywords: Martha Lagace
- 01 Apr 1999
- News
Q & A: Confronting New Technologies: When Doing Right Is Wrong
industries or certain segments of the pharmaceutical business. But in many other industries - financial services, education, and health care, for instance - this analytical... View Details
- 01 Sep 2010
- News
Fair Trade
pharmaceuticals and software, and far above the average of all industries. Many apparent paradoxes add to the puzzle posed by the industry. While rarely considered fundamentally “bad,” such as the trade in narcotics or tobacco, the beauty... View Details
- 11 Aug 2003
- Research & Ideas
Cheap, Fast, and In Control: How Tech Aids Innovation
experimentation and are triggering fundamental changes in R&D processes and performance in such fields as integrated circuit design, automotive development, and pharmaceutical drug discovery. Computer modeling and simulation, rapid... View Details
Keywords: by Wendy Guild
- 01 Sep 2015
- Blog Post
Building a Startup at HBS
Our group initially came together through a deep passion for health care – with the goal of creating a novel product that addressed an unmet need and made a tangible difference in patients’ lives. We felt that if we combined our prior experiences in the View Details
- 15 Sep 2009
- First Look
First Look: September 15
innovations. Ceteris paribus, the share of resources spent on development of general innovations, increases with the stability of the market share of the industry leader. As market shares become less persistent, the model predicts an... View Details
Keywords: Martha Lagace
- Web
Souvenirs & Novelties - The Art of American Advertising
distribute them and local retailers to print their names on them at no cost. James C. Ayer, involved in the pharmaceutical industry, reaped enormous publicity benefits from the distribution of yearly almanacs. Ayer eventually established... View Details
- 04 May 2010
- First Look
First Look: May 4
We propose that firms' corporate governance and firms' strategic business activities within an industry are interlinked. By conducting a simultaneous economic analysis of business strategy and corporate governance, scholars can better... View Details
Keywords: Martha Lagace